Cargando…

Deregulation of ARID1A, CDH1, cMET and PIK3CA and target-related microRNA expression in gastric cancer

Genetic and epigenetic alterations play an important role in gastric cancer (GC) pathogenesis. Aberrations of the phosphatidylinositol-3-kinase signaling pathway are well described. However, emerging genes have been described such as, the chromatin remodeling gene ARID1A. Our aim was to determine th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ibarrola-Villava, Maider, Llorca-Cardeñosa, Marta J., Tarazona, Noelia, Mongort, Cristina, Fleitas, Tania, Perez-Fidalgo, José Alejandro, Roselló, Susana, Navarro, Samuel, Ribas, Gloria, Cervantes, Andrés
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694964/ https://www.ncbi.nlm.nih.gov/pubmed/26334097

Ejemplares similares

Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology
por: Ibarrola-Villava, Maider, et al.
Publicado: (2016)

Epigenetic changes in localized gastric cancer: the role of RUNX3 in tumor progression and the immune microenvironment
por: Llorca-Cardeñosa, Marta Jessica, et al.
Publicado: (2016)

Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review
por: Huerta, Marisol, et al.
Publicado: (2021)

Assessing molecular subtypes of gastric cancer: microsatellite unstable and Epstein-Barr virus subtypes. Methods for detection and clinical and pathological implications
por: Martinez-Ciarpaglini, Carolina, et al.
Publicado: (2019)

Higher cMET dependence of sacral compared to clival chordoma cells: contributing to a better understanding of cMET in chordoma
por: Lohberger, Birgit, et al.
Publicado: (2021)

Sex-specific genetic effects associated with pigmentation, sensitivity to sunlight, and melanoma in a population of Spanish origin
por: Hernando, Barbara, et al.
Publicado: (2016)

Targeting the HGF-cMET Axis in Hepatocellular Carcinoma
por: Venepalli, Neeta K., et al.
Publicado: (2013)

Role of cMET in the Development and Progression of Colorectal Cancer
por: Pérez-Vargas, Juan Carlos Samamé, et al.
Publicado: (2013)

The Role of cMET in Gastric Cancer—A Review of the Literature
por: Van Herpe, Filip, et al.
Publicado: (2023)

Molecular profile in Paraguayan colorectal cancer patients, towards to a precision medicine strategy
por: Fleitas-Kanonnikoff, Tania, et al.
Publicado: (2019)

Characterization of an oncolytic adenovirus vector constructed to target the cMet receptor
por: Sakr, Hany I, et al.
Publicado: (2015)

Urinary cMet as a prognostic marker in immunoglobulin A nephropathy
por: An, Jung Nam, et al.
Publicado: (2020)

Progress of antibody-based inhibitors of the HGF–cMET axis in cancer therapy
por: Kim, Ki-Hyun, et al.
Publicado: (2017)

Structural and Molecular Insight into Resistance Mechanisms of First Generation cMET Inhibitors
por: Collie, Gavin W., et al.
Publicado: (2019)

Renoprotective effects of a novel cMet agonistic antibody on kidney fibrosis
por: Kim, Yong Chul, et al.
Publicado: (2019)

Dual Targeting of CDK4/6 and cMET in Metastatic Uveal Melanoma
por: Ohara, Masahiro, et al.
Publicado: (2021)

The utility of cMet as a diagnostic tissue biomarker in primary colorectal cancer
por: Armstrong, Gemma R., et al.
Publicado: (2021)

Targeting the cMET pathway to enhance immunotherapeutic approaches for mUM patients
por: Machiraju, Devayani, et al.
Publicado: (2023)

cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer
por: Sohn, Joohyuk, et al.
Publicado: (2014)

Soluble cMet levels in urine are a significant prognostic biomarker for diabetic nephropathy
por: Kim, Yong Chul, et al.
Publicado: (2018)

cMet agonistic antibody attenuates apoptosis in ischaemia‐reperfusion–induced kidney injury
por: An, Jung Nam, et al.
Publicado: (2020)

cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance
por: Van Der Steen, Nele, et al.
Publicado: (2015)

Non‐canonical cMet regulation by vimentin mediates Plk1 inhibitor–induced apoptosis
por: Singh, Ratnakar, et al.
Publicado: (2019)

Detection of colonic neoplasia in vivo using near-infrared-labeled peptide targeting cMet
por: Wu, Xiaoli, et al.
Publicado: (2019)

EGFL9 promotes breast cancer metastasis by inducing cMET activation and metabolic reprogramming
por: Meng, Fanyan, et al.
Publicado: (2019)

The levels of soluble cMET ectodomain in the blood of patients with ovarian cancer are an independent prognostic biomarker
por: Klotz, Daniel Martin, et al.
Publicado: (2021)

The Novel Anti-cMet Antibody seeMet 12 Potentiates Sorafenib Therapy and Radiotherapy in a Colorectal Cancer Model
por: Spiegelberg, Diana, et al.
Publicado: (2020)

Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer
por: Papaccio, Federica, et al.
Publicado: (2020)

RUNAT-BI: A Ruthenium(III) Complex as a Selective Anti-Tumor Drug Candidate against Highly Aggressive Cancer Cell Lines
por: Albanell-Fernández, Marta, et al.
Publicado: (2022)

The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer
por: Chae, Young Kwang, et al.
Publicado: (2016)

Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells
por: Vengoji, Raghupathy, et al.
Publicado: (2019)

EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma
por: Colombino, Maria, et al.
Publicado: (2019)

cMetS Based on Z-Scores as an Accurate and Efficient Scoring System to Determine Metabolic Syndrome in Spanish Adolescents
por: Fernández-Aparicio, Ángel, et al.
Publicado: (2022)

Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress
por: Gambardella, Valentina, et al.
Publicado: (2020)

Personalized Medicine: Recent Progress in Cancer Therapy
por: Gambardella, Valentina, et al.
Publicado: (2020)

Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties
por: Castoldi, R., et al.
Publicado: (2012)

Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model
por: Brandes, Franziska, et al.
Publicado: (2015)

Synergistic antitumor effects of cMet inhibitor in combination with anti-VEGF in colorectal cancer patient-derived xenograft models
por: Chen, Xiangheng, et al.
Publicado: (2018)

Targeted Co-Delivery of Docetaxel and cMET siRNA for Treatment of Mucin1 Overexpressing Breast Cancer Cells
por: Majidi Zolbanin, Naime, et al.
Publicado: (2018)

Luteolin exerts a marked antitumor effect in cMet-overexpressing patient-derived tumor xenograft models of gastric cancer
por: Lu, Jun, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_57nvl7pmmqas1t33mem7bd7s9p